CU24438B1 - COMPOUNDS DERIVED FROM 1,6 NAPHTHYRIDINE-DIONE ACTIVE AS SENSE MUTATION SUPPRESSORS - Google Patents
COMPOUNDS DERIVED FROM 1,6 NAPHTHYRIDINE-DIONE ACTIVE AS SENSE MUTATION SUPPRESSORSInfo
- Publication number
- CU24438B1 CU24438B1 CU2016000182A CU20160182A CU24438B1 CU 24438 B1 CU24438 B1 CU 24438B1 CU 2016000182 A CU2016000182 A CU 2016000182A CU 20160182 A CU20160182 A CU 20160182A CU 24438 B1 CU24438 B1 CU 24438B1
- Authority
- CU
- Cuba
- Prior art keywords
- naphthyridine
- compounds derived
- sense mutation
- dione
- active
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- KVOHQTLDEXUTGJ-UHFFFAOYSA-N 1,6-naphthyridine-2,3-dione Chemical compound O=C1C(N=C2C=CN=CC2=C1)=O KVOHQTLDEXUTGJ-UHFFFAOYSA-N 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 title 1
- 108020004485 Nonsense Codon Proteins 0.000 abstract 2
- 230000037434 nonsense mutation Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
<p>La invención se refiere a compuestos derivados de 1,6-naftiridina-diona de fórmula (I'):</p> <p>ESPACIO PARA FÓRMULA</p> <p>o a una sal del mismo, activos como supresores de mutación sin sentido, en donde los sustituyentes son como se definen en el Capítulo descriptivo. La ventaja de los compuestos de la invención es que promueven la lectura de traducción teniendo valores de AC50 para la supresión de la mutación sin sentido entre 0.4 y 22 uM.</p><p> The invention relates to compounds derived from 1,6-naphthyridine-dione of formula (I '): </p> <p> SPACE FOR FORMULA </p> <p> or to a salt thereof, active as nonsense mutation suppressors, where the substituents are as defined in the Descriptive Chapter. The advantage of the compounds of the invention is that they promote translational reading, having AC50 values for the suppression of the nonsense mutation between 0.4 and 22 uM. </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170976 | 2014-06-03 | ||
| PCT/IB2015/054174 WO2015186063A1 (en) | 2014-06-03 | 2015-06-02 | Naphthyridinedione derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160182A7 CU20160182A7 (en) | 2017-03-03 |
| CU24438B1 true CU24438B1 (en) | 2019-09-04 |
Family
ID=50841689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000182A CU24438B1 (en) | 2014-06-03 | 2015-06-02 | COMPOUNDS DERIVED FROM 1,6 NAPHTHYRIDINE-DIONE ACTIVE AS SENSE MUTATION SUPPRESSORS |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10138232B2 (en) |
| EP (1) | EP3152209B1 (en) |
| JP (2) | JP6343034B2 (en) |
| KR (1) | KR101905295B1 (en) |
| CN (1) | CN106459043B (en) |
| AP (1) | AP2016009545A0 (en) |
| AR (1) | AR100706A1 (en) |
| AU (2) | AU2015270125B2 (en) |
| BR (1) | BR112016027383A8 (en) |
| CA (1) | CA2950724A1 (en) |
| CL (1) | CL2016003081A1 (en) |
| CR (1) | CR20160565A (en) |
| CU (1) | CU24438B1 (en) |
| EA (1) | EA030374B1 (en) |
| EC (1) | ECSP16096831A (en) |
| ES (1) | ES2731802T3 (en) |
| GT (1) | GT201600252A (en) |
| IL (1) | IL248773B (en) |
| MX (1) | MX374245B (en) |
| MY (1) | MY178379A (en) |
| PE (1) | PE20170086A1 (en) |
| PH (2) | PH12016502293B1 (en) |
| SG (1) | SG11201609209YA (en) |
| SV (1) | SV2016005331A (en) |
| TN (1) | TN2016000490A1 (en) |
| TW (1) | TWI688565B (en) |
| UY (1) | UY36150A (en) |
| WO (1) | WO2015186063A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6343034B2 (en) | 2014-06-03 | 2018-06-13 | ノバルティス アーゲー | Naphthyridinedione derivatives |
| JP6560257B2 (en) * | 2014-06-03 | 2019-08-14 | ノバルティス アーゲー | Pyrimido [4,5-b] quinoline-4,5 (3H, 10H) -dione derivative |
| CN106414443B (en) * | 2014-06-03 | 2018-10-26 | 诺华股份有限公司 | Pyridopyrimidine dione derivative |
| WO2019225625A1 (en) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | Readthrough inducer and pharmaceutical use thereof |
| JP7570921B2 (en) | 2018-07-24 | 2024-10-22 | ソニーセミコンダクタソリューションズ株式会社 | Semiconductor Device |
| WO2024161623A1 (en) * | 2023-02-03 | 2024-08-08 | 株式会社 RINAT Imaging | Readthrough drug, use of nucleic acid probe and readthrough combination agent |
| CN117756607A (en) * | 2023-12-01 | 2024-03-26 | 陕西煤业化工技术研究院有限责任公司 | Process and system for producing high-value xylenol by xylenol fraction isomerization |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (en) | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | Anticancer agent containing 5-deazaflavin compound as active ingredient |
| JP2989871B2 (en) * | 1989-08-30 | 1999-12-13 | 大日本製薬株式会社 | Tricyclic compounds |
| DE4035479A1 (en) | 1990-11-08 | 1992-05-14 | Basf Ag | SUBSTITUTED PYRIDO (2,3-D) PYRIMIDINE-2,4 (1H, 3H) DIONE |
| WO1996028444A1 (en) | 1995-03-15 | 1996-09-19 | Pfizer Inc. | 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS |
| US6016875A (en) * | 1998-02-10 | 2000-01-25 | Case Corporation | Gain adaptation control for hydraulic systems |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003249244A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| EP4101846B1 (en) | 2003-04-11 | 2023-08-02 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| RS56037B1 (en) | 2004-06-24 | 2017-09-29 | Vertex Pharma | ATP-BINDING CASSETTE TRANSPORT MODULATORS |
| CN101076703A (en) * | 2004-10-13 | 2007-11-21 | Ptc医疗公司 | Compounds and their use for treating somatic mutation-related diseases |
| EP2390255B1 (en) | 2006-04-03 | 2016-07-13 | Technion Research & Development Foundation Ltd. | Novel aminoglycosides and uses thereof in the treatment of genetic disorders |
| CA2660951A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
| JP5686596B2 (en) | 2007-05-25 | 2015-03-18 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Regulators of cystic fibrosis transmembrane conductance regulator |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2422817A1 (en) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flavin-nucleic acid ligand conjugates |
| ES2710854T3 (en) * | 2010-08-05 | 2019-04-29 | Univ Lille | Compound useful for the treatment of diseases mediated by a nonsense mutation and pharmaceutical composition comprising said compound |
| HK1209637A1 (en) * | 2012-12-13 | 2016-04-08 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
| JP6560257B2 (en) | 2014-06-03 | 2019-08-14 | ノバルティス アーゲー | Pyrimido [4,5-b] quinoline-4,5 (3H, 10H) -dione derivative |
| CN106414443B (en) | 2014-06-03 | 2018-10-26 | 诺华股份有限公司 | Pyridopyrimidine dione derivative |
| JP6343034B2 (en) | 2014-06-03 | 2018-06-13 | ノバルティス アーゲー | Naphthyridinedione derivatives |
-
2015
- 2015-06-02 JP JP2016570886A patent/JP6343034B2/en not_active Expired - Fee Related
- 2015-06-02 CR CR20160565A patent/CR20160565A/en unknown
- 2015-06-02 CU CU2016000182A patent/CU24438B1/en unknown
- 2015-06-02 PE PE2016002514A patent/PE20170086A1/en unknown
- 2015-06-02 CA CA2950724A patent/CA2950724A1/en not_active Abandoned
- 2015-06-02 BR BR112016027383A patent/BR112016027383A8/en active Search and Examination
- 2015-06-02 SG SG11201609209YA patent/SG11201609209YA/en unknown
- 2015-06-02 ES ES15731121T patent/ES2731802T3/en active Active
- 2015-06-02 EP EP15731121.8A patent/EP3152209B1/en active Active
- 2015-06-02 MX MX2016015856A patent/MX374245B/en active IP Right Grant
- 2015-06-02 WO PCT/IB2015/054174 patent/WO2015186063A1/en not_active Ceased
- 2015-06-02 MY MYPI2016704068A patent/MY178379A/en unknown
- 2015-06-02 EA EA201692270A patent/EA030374B1/en not_active IP Right Cessation
- 2015-06-02 US US14/728,613 patent/US10138232B2/en active Active
- 2015-06-02 CN CN201580029417.3A patent/CN106459043B/en not_active Expired - Fee Related
- 2015-06-02 AR ARP150101737A patent/AR100706A1/en unknown
- 2015-06-02 TN TN2016000490A patent/TN2016000490A1/en unknown
- 2015-06-02 AP AP2016009545A patent/AP2016009545A0/en unknown
- 2015-06-02 AU AU2015270125A patent/AU2015270125B2/en not_active Ceased
- 2015-06-02 KR KR1020167033550A patent/KR101905295B1/en not_active Expired - Fee Related
- 2015-06-02 TW TW104117848A patent/TWI688565B/en not_active IP Right Cessation
- 2015-06-03 UY UY0001036150A patent/UY36150A/en not_active Application Discontinuation
-
2016
- 2016-11-06 IL IL248773A patent/IL248773B/en active IP Right Grant
- 2016-11-17 PH PH12016502293A patent/PH12016502293B1/en unknown
- 2016-11-30 CL CL2016003081A patent/CL2016003081A1/en unknown
- 2016-12-02 SV SV2016005331A patent/SV2016005331A/en unknown
- 2016-12-02 GT GT201600252A patent/GT201600252A/en unknown
- 2016-12-28 EC ECIEPI201696831A patent/ECSP16096831A/en unknown
-
2018
- 2018-01-18 AU AU2018200421A patent/AU2018200421A1/en not_active Withdrawn
- 2018-05-17 JP JP2018095248A patent/JP2018138609A/en active Pending
- 2018-08-13 PH PH12018501709A patent/PH12018501709A1/en unknown
- 2018-10-10 US US16/156,447 patent/US20190248784A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24438B1 (en) | COMPOUNDS DERIVED FROM 1,6 NAPHTHYRIDINE-DIONE ACTIVE AS SENSE MUTATION SUPPRESSORS | |
| SV2016005180A (en) | AMINO-HETEROARIL-BENZAMIDAS AS CINASA INHIBITORS | |
| CU24411B1 (en) | COMPOSITE DERIVED FROM BENZAMIDE REPLACED WITH 1,3-TIAZOL-2-ILO USEFUL FOR THE TREATMENT OF NEUROGENIC DISORDERS | |
| UY36315A (en) | NEW INTEGRINE ANTIGONIST COMPOUNDS avß6. | |
| ECSP17010156A (en) | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | |
| EA201692526A1 (en) | SUBSTITUTED [1,2,4] TRIAZOLE COMPOUNDS | |
| CR20160564A (en) | CYCLIC DINUCLEOTIDES AS STING MODULATORS | |
| MX2018006148A (en) | Inhibitors of cxcr2. | |
| EA201692203A1 (en) | TANK-BINDING KINAZ INHIBITING COMPOUNDS | |
| CO2018000589A2 (en) | Oxiesterols and pharmaceutical compositions containing them | |
| EA201691857A1 (en) | COMPOUNDS APPLICABLE AS IMMUNOMODULATORS | |
| EA201691913A1 (en) | SUBSTITUTED [1,2,4] TRIAZOL AND IMIDAZOL COMPOUNDS AS FUNGICIDES | |
| EA201890052A1 (en) | REGULATORS NRF2 | |
| SV2017005405A (en) | COMPOUNDS AND COMPOSITIONS AS QUINASA RAF INHIBITORS | |
| CL2017000792A1 (en) | Boronic Acid Derivatives | |
| DOP2015000201A (en) | AZABENCIMIDAZOL COMPOUNDS AS INHIBITORS OF PDEN4 ISOENZIMAS FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS | |
| EA201690844A1 (en) | GSK-3 INHIBITORS | |
| CU20150061A7 (en) | PIRIMIDO- [4,5-b] -QUINOLINA-4,5 (3H, 10H) -DIONAS AS MUTATION SUPPRESSORS WITHOUT SENSE | |
| EA201691982A1 (en) | 5,6-Disposable Pyridine-2-Carboxamides as Agonists of Cannabinoid Receptors | |
| CU20170007A7 (en) | IMIDAZOPIRIDAZINE COMPOUNDS | |
| MX2019009606A (en) | Bis-compounds for optically active devices. | |
| EA201691983A1 (en) | Pyridine-2-amides suitable as agonists of CB2 | |
| CL2017000484A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| EA201692289A1 (en) | SUBSTITUTED [1,2,4] TRIAZOL AND IMIDAZOL COMPOUNDS AS FUNGICIDES | |
| AR105821A1 (en) | USEFUL COMPOUNDS TO INHIBIT ROR-g-T |